Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Annals of Neurology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 11921054
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

  2001cited by this paper
• Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis.

  2000cited by this paper
• Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

  2000cited by this paper
• Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination.

  1999cited by this paper
• Multisequence MRI in clinically isolated syndromes and the early development of MS

  1999cited by this paper
• Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS

  1999cited by this paper
• Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

  1998cited by this paper
• The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up.

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

  1998cited by this paper
• Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.

  1997cited by this paper
• Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

  1996cited by this paper
• The effect of gadolinium on the sensitivity and specificity of MR in the initial diagnosis of multiple sclerosis.

  1995cited by this paper
• The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group.

  1993cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.

  1992cited by this paper
• Methylprednisolone and multiple sclerosis.

  1988cited by this paper
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

  1983cited by this paper

• Exploring the Pathophysiology, Diagnosis, and Treatment Options of Multiple Sclerosis.

  2025cites this paper
• The need for a strategic therapeutic approach: multiple sclerosis in check

  2022cites this paper
• ĐẶC ĐIỂM LÂM SÀNG CỦA BỆNH NHÂN XƠ CỨNG RẢI RÁC, ĐIỀU TRỊ TẠI KHOA THẦN KINH, BỆNH VIỆN BẠCH MAI TỪ 1/2018-7/2020

  2022cites this paper
• Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)

  2021influential citation
• Babesia microti infection in a patient with Multiple Sclerosis treated with Ocrelizumab.

  2021cites this paper
• Autoimmune and demyelinating optic neuritis.

  2020cites this paper
• Assessment of delayed diagnosis and treatment in multiple sclerosis patients during 1990–2016

  2020cites this paper
• Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.

  2020cites this paper
• Clinical Parameters to Predict Future Clinical Disease Activity After Treatment Change to Higher-Dose Subcutaneous Interferon Beta-1a From Other Platform Injectables in Patients With Relapsing-Remitting Multiple Sclerosis

  2020cites this paper
• Drug Treatment of Clinically Isolated Syndrome

  2019cites this paper
• Clinically Isolated Syndrome and Early Relapsing Multiple Sclerosis.

  2019cites this paper
• Targeted Oligodendrocyte Apoptosis in Optic Nerve Leads to Persistent Demyelination

  2019cites this paper
• Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.

  2017cites this paper
• Valoración de la discromatopsia adquirida mediante nueva aplicación informática en pacientes con neuropatías ópticas desmielinizantes

  2017cites this paper
• Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis

  2017cites this paper
• Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice

  2017cites this paper
• Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.

  2017cites this paper
• Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study

  2016cites this paper
• SclerosisDiagnosis and Follow-Up of Multiple MRI Protocol and Clinical Guidelines for the Standardized of MS Centers Task Force for a Revised Recommendations of the Consortium

  2016cites this paper
• Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis

  2016cites this paper
• Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring

  2015cites this paper
• TRANSFER FACTOR, IN VIVO

  2015cites this paper
• Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome.

  2014cites this paper
• Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study

  2014cites this paper
• [Sema4A as a biomarker predicting responsiveness to IFN β treatment].

  2014cites this paper
• Acute inflammatory myelopathies.

  2014cites this paper
• RELAPSİNG REMİTTİNG MULTİPL SKLEROZ VE KLİNİK İZOLE SENDROM GRUPLARINDA 25 (OH) D VİTAMİN DÜZEYİ

  2014cites this paper
• Risk of multiple sclerosis after optic neuritis in patients with normal baseline brain MRI.

  2014cites this paper
• Early prognosis of multiple sclerosis.

  2014cites this paper
• Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes

  2013cites this paper
• Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study

  2013cites this paper
• Novel Immunomodulatory Approaches for the Management of Multiple Sclerosis

  2013cites this paper
• Association of Multiple Sclerosis Susceptibility Variants and Early Attack Location in the CNS

  2013cites this paper
• Roles of Sema4A in multiple sclerosis and interferon‐β therapy efficacy

  2013cites this paper
• Approved Beta Interferons in Relapsing-Remitting Multiple Sclerosis: Is There an Odd One Out?

  2012cites this paper
• Early Diagnosis, Monitoring, and Treatment of Optic Neuritis

  2012influential citation
• Neuroimaging in Multiple Sclerosis

  2012cites this paper
• Interferon Beta and Glatiramer Acetate Therapy

  2012cites this paper
• Shifting imaging targets in multiple sclerosis: From inflammation to neurodegeneration

  2012cites this paper
• Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon.

  2012cites this paper
• Neurologic emergencies: case studies.

  2012cites this paper
• Study on diffusion tensor imaging of cervical spinal cord in patients with multiple sclerosis

  2012cites this paper
• Utility of Lorenz Curves in Examining Physician Prescribing Practices: Example of Ontario Neurologist Prescribing of Multiple Sclerosis Disease-modifying Therapies in 2009

  2012cites this paper
• Clinical isolated syndrome: a 3-year follow-up study in China.

  2011cites this paper
• Memory B cells from a subset of treatment naïve relapsing remitting multiple sclerosis patients elicit CD4+ T cell proliferation and IFN-γ production in response to MBP and MOG

  2011cites this paper
• A Classical Presentation of Optic Neuritis Leading to a Non-classical Case of Multiple Sclerosis

  2011cites this paper
• Predictive factors for multiple sclerosis in patients with clinically isolated spinal cord syndrome

  2011cites this paper
• Memory B cells from a subset of treatment‐naïve relapsing‐remitting multiple sclerosis patients elicit CD4+ T‐cell proliferation and IFN‐γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein

  2010cites this paper
• Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis

  2010cites this paper
• Cognitive impairment in clinically isolated syndrome: A systematic review

  2010cites this paper
• New developments in the treatment of optic neuritis.

  2010cites this paper
• The effect of interferon β-1a on optic neuritis relapse in patients with multiple sclerosis

  2010cites this paper
• The contribution of brain reorganisation to recovery inpatients with optic neuritis

  2010cites this paper
• Eye disorders in patients with multiple sclerosis: natural history and management

  2010cites this paper
• Management of optic neuritis and impact of clinical trials: an international survey.

  2009cites this paper
• Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis.

  2009cites this paper
• Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria

  2009cites this paper
• Glatiramer acetate treatment in PPMS: why males appear to respond favorably.

  2009cites this paper
• Optic neuritis: a review.

  2009cites this paper
• Immunotherapy of multiple sclerosis

  2009cites this paper
• Demyelinating Disorders of the Central Nervous System

  2009cites this paper
• Early treatment of multiple sclerosis: A Latin American Experts Meeting

  2009cites this paper
• Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.

  2009cites this paper
• Relapse Management in Multiple Sclerosis

  2009influential citation
• Magnetic resonance imaging in clinical trials

  2008cites this paper
• Genetics and Natural History of Multiple Sclerosis

  2008cites this paper
• Management and Care – The Changing Landscape of Multiple Sclerosis

  2008cites this paper
• Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b

  2008cites this paper
• The definition of non-responder to multiple sclerosis treatment: neuroimaging markers

  2008cites this paper
• Towards immunotherapeutic drugs and vaccines against multiple sclerosis.

  2008cites this paper
• Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

  2008cites this paper
• Management of Optic Neuritis in Canada: Survey of Ophthalmologists and Neurologists

  2008cites this paper
• [Management of isolated optic neuritis in France: survey of neurologists and ophthalmologists].

  2008cites this paper
• Acute Inflammatory Demyelinating Optic Neuritis: Evidence-Based Visual and Neurological Considerations

  2008cites this paper
• [Choice of early and escalation treatment options for multiple sclerosis].

  2008cites this paper
• Immunomodulatory treatment strategies in multiple sclerosis

  2008cites this paper
• The clinical epidemiology of multiple sclerosis.

  2008cites this paper
• Clinical approach to optic neuropathies

  2007cites this paper
• Interferons in multiple sclerosis: ten years' experience.

  2007cites this paper
• The role of optical coherence tomography in multiple sclerosis: expert panel consensus.

  2007cites this paper
• Control of multiple sclerosis relapses with immunomodulating agents.

  2007cites this paper
• Optic Neuritis

  2007cites this paper
• Acute fulminant demyelinating disease: a descriptive study of 60 patients.

  2007cites this paper
• Interferon Beta in Acute Optic Neuritis

  2006cites this paper
• Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

  2006cites this paper
• A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

  2006cites this paper
• Not every patient with multiple sclerosis should be treated at time of diagnosis.

  2006cites this paper
• Drug Insight: interferon treatment in multiple sclerosis

  2006cites this paper
• Optical coherence tomography in multiple sclerosis.

  2006cites this paper
• Risk of Confirmed MS According to Treatment Tracked for 4 Years : Oral Prednisone Versus Intravenous Methylprednisolone

  2006cites this paper
• [The optic neuropathies].

  2005cites this paper
• Acute inflammatory demyelinating optic neuritis: current concepts in diagnosis and management.

  2005cites this paper
• Powering our way to the elusive side effect: a composite outcome 'basket' of predefined designated endpoints in each organ system should be included in all controlled trials.

  2005cites this paper
• Interferons in multiple sclerosis.

  2005cites this paper
• Evaluation of Functional Status during Beta-Interferon Therapy

  2005cites this paper
• [Recent advances in pathogenesis and therapy of multiple sclerosis].

  2005cites this paper
• Leczenie immunomodulujące stwardnienia rozsianego o wczesnym początku The immunomodulatory treatment in early onset multiple sclerosis

  2005cites this paper
• Intramuscular interferon-beta-1a: in patients at high risk of developing clinically definite multiple sclerosis.

  2005cites this paper
• Genomics and proteomics: role in the management of multiple sclerosis

  2005cites this paper
• Defining the response to multiple sclerosis treatment: the role of conventional magnetic resonance imaging

  2005cites this paper